According to Precision Business Insights, the Uveitis Treatment Market research report provides industry size and growth.
According to Precision Business Insights (PBI), the latest report the global uveitis treatment market is expected to be worth USD 581 million in 2022 and projected to grow at 5.7% CAGR from 2023 to 2029. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. Uveitis is swelling of the middle layer of the eye, which is called the uvea. It may occur from both infectious and non-infectious causes. It is a group of inflammatory diseases affecting eyes and can cause loss of vision. Causes of uveitis include infections such as brucellosis, leptospirosis, syphilis, tuberculosis, autoimmune diseases such as sarcoidosis, Crohn'™s disease, multiple sclerosis, arthritis, ankylosing spondylitis, and psoriatic arthritis. In addition, uveitis is also caused by drugs such as Rifabutin and moxifloxacin. The growth of uveitis drugs market is due to rise in prevalence and complications related to uveitis. In addition, increase in prevalence rates, market players betting heavily on R & D to develop new drugs, an introduction of biologics into the market, fast approval of the drugs are fueling the market growth of global uveitis treatment market. However, few factors are restraining the growth of the market such as side effects of the drugs, eye irritation and lack of awareness about eye disorders in undeveloped regions, lack of sufficient healthcare infrastructure is hindering the non-infectious uveitis treatment market. The global uveitis treatment market is categorized as-
By Drug class
By Disease type
By Type of cause
Hospital Pharmacies, retail pharmacies and others And lastly on the basis of geographical regions global uveitis treatment market segmented into following regions-North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is leading in global uveitis treatment market due to various factors such as early approval of drugs compared to other regions, increased R & D investments by market players, and high prevalence of the uveitis is contributing growth of the market. In Europe region due to increased prevalence of diseases such as HIV, multiple sclerosis that are underlying causes of uveitis conditions. Japan, China, and India are expected to play important role in the revenue growth of the Asia-Pacific uveitis treatment market due to rapidly developing healthcare infrastructure, increased R & D expenditure and growing awareness about the eye-related diseases. However, manufacturing of eye preparations required aseptic conditions and the manufacturing plant should be GMP certified. Hence the cost related to these preparations is very high that has the direct implication on a cost of the drugs.
Some of the key players in uveitis drugs market include AbbVie Inc. (U.S.), Eyegate Pharmaceuticals Inc. (US), Valeant Pharmaceuticals (Bausch + Lomb) (Canada), Novartis AG (Switzerland), Alimera Sciences Inc. (U.S.) and Santen Pharmaceutical Co. Ltd (Japan)
USFDA approved AbbVie'™s HUMIRA for the treatment of non-infectious intermediate, posterior and Panuveitis. Market players are developing novel molecules that can treat uveitis conditions in order to enhance their sales revenue. Companies are focusing on the development of the various drugs in the treatment of the Uveitis. For instance, Aurinia Pharmaceuticals Inc. developing Luvenia, a calcineurin inhibitor for the treatment of noninfectious Uveitis. Considering the above-mentioned factors non-infectious uveitis treatment market is expected to grow at the significant rate.